EP3846787A4 - Nouvelle composition de lapatinib de forme galénique orale solide et procédé de fabrication - Google Patents

Nouvelle composition de lapatinib de forme galénique orale solide et procédé de fabrication Download PDF

Info

Publication number
EP3846787A4
EP3846787A4 EP19857473.3A EP19857473A EP3846787A4 EP 3846787 A4 EP3846787 A4 EP 3846787A4 EP 19857473 A EP19857473 A EP 19857473A EP 3846787 A4 EP3846787 A4 EP 3846787A4
Authority
EP
European Patent Office
Prior art keywords
lapatinib
manufacturing
dosage form
solid dosage
oral solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19857473.3A
Other languages
German (de)
English (en)
Other versions
EP3846787A1 (fr
Inventor
Dharmesh Mahendrabhai Shah
Aravind Manappa Badiger
Mukeshkumar Subhashchandra SHARMA
Madhavkumar Dilipbhai TRIVEDI
Harikrishnabhai Vinubhai PATEL
Prashant Karamshibhai PATEL
Prashant Kanaiyalal GANDHI
Nimitkumar Harishchandra PANCHAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bdr Pharmaceuticals International Private Ltd
Original Assignee
Bdr Pharmaceuticals International Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bdr Pharmaceuticals International Private Ltd filed Critical Bdr Pharmaceuticals International Private Ltd
Publication of EP3846787A1 publication Critical patent/EP3846787A1/fr
Publication of EP3846787A4 publication Critical patent/EP3846787A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP19857473.3A 2018-09-03 2019-08-30 Nouvelle composition de lapatinib de forme galénique orale solide et procédé de fabrication Pending EP3846787A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201821032977 2018-09-03
PCT/IB2019/057324 WO2020049429A1 (fr) 2018-09-03 2019-08-30 Nouvelle composition de lapatinib de forme galénique orale solide et procédé de fabrication

Publications (2)

Publication Number Publication Date
EP3846787A1 EP3846787A1 (fr) 2021-07-14
EP3846787A4 true EP3846787A4 (fr) 2022-05-25

Family

ID=69723001

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19857473.3A Pending EP3846787A4 (fr) 2018-09-03 2019-08-30 Nouvelle composition de lapatinib de forme galénique orale solide et procédé de fabrication

Country Status (7)

Country Link
EP (1) EP3846787A4 (fr)
BR (1) BR112021004047A2 (fr)
CL (1) CL2021000512A1 (fr)
MX (1) MX2021002441A (fr)
PH (1) PH12021550451A1 (fr)
WO (1) WO2020049429A1 (fr)
ZA (1) ZA202101538B (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010023187A1 (fr) * 2008-08-25 2010-03-04 Ratiopharm Gmbh Composition pharmaceutique contenant de la n-[3-chloro-4-[(3-fluorophényl)méthoxy]phényl]-6-[5[[[2-(méthylsulfonyl)éthyl]amino]méthyl]-2-furyl]-4-quinazolinamine
WO2010023188A1 (fr) * 2008-08-25 2010-03-04 Ratiopharm Gmbh Composition pharmaceutique contenant de la n-[3-chloro-4-[(3-fluorophényl)méthoxy]phényl]-6-[5[[[2-(méthylsulfonyl)éthyl]amino]méthyl]-2-furyl]-4-quinazolinamine
WO2011146710A1 (fr) * 2010-05-21 2011-11-24 Glaxosmithkline Llc Combinaison
CN106511289A (zh) * 2015-09-10 2017-03-22 湖北生物医药产业技术研究院有限公司 甲苯磺酸拉帕替尼片剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130131090A1 (en) * 2010-08-03 2013-05-23 Bandi Parthasaradhi Reddy Salts of lapatinib
WO2015145145A1 (fr) * 2014-03-24 2015-10-01 Cipla Limited Composition pharmaceutique contenant du lapatinib

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010023187A1 (fr) * 2008-08-25 2010-03-04 Ratiopharm Gmbh Composition pharmaceutique contenant de la n-[3-chloro-4-[(3-fluorophényl)méthoxy]phényl]-6-[5[[[2-(méthylsulfonyl)éthyl]amino]méthyl]-2-furyl]-4-quinazolinamine
WO2010023188A1 (fr) * 2008-08-25 2010-03-04 Ratiopharm Gmbh Composition pharmaceutique contenant de la n-[3-chloro-4-[(3-fluorophényl)méthoxy]phényl]-6-[5[[[2-(méthylsulfonyl)éthyl]amino]méthyl]-2-furyl]-4-quinazolinamine
WO2011146710A1 (fr) * 2010-05-21 2011-11-24 Glaxosmithkline Llc Combinaison
CN106511289A (zh) * 2015-09-10 2017-03-22 湖北生物医药产业技术研究院有限公司 甲苯磺酸拉帕替尼片剂及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2020049429A1 *

Also Published As

Publication number Publication date
CL2021000512A1 (es) 2021-11-26
ZA202101538B (en) 2022-07-27
MX2021002441A (es) 2021-03-25
EP3846787A1 (fr) 2021-07-14
WO2020049429A1 (fr) 2020-03-12
BR112021004047A2 (pt) 2021-05-25
PH12021550451A1 (en) 2021-09-27

Similar Documents

Publication Publication Date Title
EP3896062A4 (fr) Composé d'isoindoline, procédé de préparation, composition pharmaceutique et utilisation du composé d'isoindoline
EP3755310A4 (fr) Composition pour film pour voie transmucosale et procédés de préparation et d'utilisation de celle-ci
EP3586790A4 (fr) Plaque de prothèse dentaire et son procédé de fabrication, dent artificielle et son procédé de fabrication, et prothèse dentaire à plaque et son procédé de fabrication
EP3740576A4 (fr) Compositions thérapeutiques et leurs procédés de préparation et d'utilisation
EP3976070A4 (fr) Compositions organoïdes façonnées et leurs procédés de fabrication
EP3606493A4 (fr) Compositions de ciment dentaires et procédés d'utilisation
EP3891247A4 (fr) Compositions de ciment géopolymère et procédés d'utilisation
EP3760191A4 (fr) Composition pharmaceutique, procédé de préparation et utilisation de cette dernière
EP3738583A4 (fr) Composite de silicate stratifié-médicament, destiné à améliorer la biodisponibilité orale, composition pharmaceutique orale le comprenant, et procédé de fabrication de composite
PL4048230T3 (pl) Doustne kompozycje gliptiny i sposób ich wytwarzania
ZA202201541B (en) Oral formulations of edaravone and method of manufacturing thereof
EP4034109A4 (fr) Méthode et composition pour le traitement d'une maladie
EP3485886A4 (fr) Composition pharmaceutique de tecovirimat à administration orale et sa méthode de préparation
EP3766880A4 (fr) Forme solide d'un composé de dihydropyrimidine, son procédé de préparation et son utilisation
IL292682A (en) Formulation of x842 for oral administration
EP3836938A4 (fr) Formes solides de benzoxaborole substitué et compositions associées
EP3781145A4 (fr) Compositions de film à désintégration orale de paracétamol
EP3947411A4 (fr) Composés cycliques et leurs procédés de fabrication et d'utilisation
EP4062906A4 (fr) Composition pharmaceutique orale comprenant un composé carbamate et procédé de préparation de cette composition
EP4022700A4 (fr) Matériaux et procédés de fabrication
EP3813842A4 (fr) Composition pharmaceutique et son procédé de préparation
EP3897181A4 (fr) Formulations pour immunothérapie orale par l'?uf, procédés de fabrication et traitements pour l'allergie à l'?uf
EP3801539A4 (fr) Compositoins pharmaceutiques solides d'administration par voie orale comprenant de la linagliptine
EP3740500A4 (fr) Compositions et procédés permettant d'augmenter l'expression de scn2a
EP3846787A4 (fr) Nouvelle composition de lapatinib de forme galénique orale solide et procédé de fabrication

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210401

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220426

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 405/04 20060101ALI20220420BHEP

Ipc: A61K 31/517 20060101ALI20220420BHEP

Ipc: A61K 9/20 20060101AFI20220420BHEP